Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an update.
Lumos Diagnostics has released real-world data on its FebriDx® test, presented at the Primary Care Respiratory Society Annual Conference. The data highlights the test’s effectiveness in reducing antibiotic prescriptions, improving patient experiences, and generating significant cost savings for healthcare systems by distinguishing between viral and bacterial infections. This development underscores the potential of FebriDx® to enhance clinical decision-making, address antimicrobial resistance, and optimize healthcare resource utilization.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 7,474,830
Technical Sentiment Signal: Buy
Current Market Cap: A$117.9M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.